Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 05 - 05 entities : Argenx se save search
Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
Published: 2022-05-05 (Crawled : 16:00) - globenewswire.com
ZLAB | $14.97 6.4% 6.01% 460K
|
Health Technology
|
| O: -1.73%
H: 0.38%
C: -3.24%
ARGX | $369.01 2.44% 2.38% 320K
|
Health Technology
|
| O: 3.33%
H: 6.9%
C: 4.68%
vyvgart trial positive phase 3
argenx Reports First Quarter 2022 Financial Results and Provides Business Update
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
ARGX | $369.01 2.44% 2.38% 320K
|
Health Technology
|
| O: 3.33%
H: 6.9%
C: 4.68%
results
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
ARGX | $369.01 2.44% 2.38% 320K
|
Health Technology
|
| O: 3.33%
H: 6.9%
C: 4.68%
vyvgart trial positive phase 3
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.